Safety, reactogenicity, and immunogenicity of Ad26.COV2.S as homologous or heterologous COVID-19 booster vaccination: Results of a randomized, double-blind, phase 2 trial
Author:
Le Gars Mathieu,
Sadoff Jerald,
Cárdenas Vicky,
Heerwegh Dirk,
Tesfaye Fisseha,
Roey Griet Van,
Spicer Colleen,
Matias Samantha Santoro,
Crayne Olivia,
Kamphuis Tobias,
Struyf FrankORCID,
Schuitemaker HannekeORCID,
Douoguih Macaya
Reference35 articles.
1. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19;Sadoff;N Engl J Med,2021
2. Final analysis of efficacy and safety of single-dose Ad26.COV2.S;Sadoff;N Engl J Med,2022
3. Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial;Hardt;Lancet Infect Dis,2022
4. SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3;Falsey;N Engl J Med,2021
5. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis;Choi;Nat Med,2021
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献